Real-World Outcomes and Safety of JAK Inhibitors in Pediatric Alopecia Areata: A Retrospective Multicenter Study

    August 2026 in “ Australasian Journal of Dermatology ”
    Miguel Mansilla‐Polo, A. Giacaman, Carlos Abril‐Pérez … Montserrat Évole‐Buselli
    Studysummary This study observed that in a real-world pediatric setting, Janus kinase inhibitors led to improvements in scalp, eyebrow, and eyelash involvement in children with alopecia areata, with a generally favorable tolerability profile, though baseline imbalances and non-randomized treatment allocation limit causal conclusions and drug comparisons.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 12

    1. Systemic Therapies for Pediatric Alopecia Areata PubMed · 2025
    2. Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata Clinical and Experimental Dermatology · 2024
    3. Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of the Literature Dermatology Practical & Conceptual · 2024
    4. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    5. Dupilumab for the Treatment of Alopecia Areata in Pediatric Patients with Atopic Dermatitis: A Scoping Review Pediatric Dermatology · 2024
    6. Psychosocial Comorbidities in Patients With Pediatric Alopecia Areata: A Literature Review Clinical and Experimental Dermatology · 2024
    7. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    8. The New Era of JAK Inhibitors: Impelling Updates in Alopecia Areata Guideline Journal of the European Academy of Dermatology and Venereology · 2023
    9. Exploring the Efficacy of Baricitinib in Treating Alopecia Areata After Failed Janus Kinase Inhibitor Therapy JAAD Case Reports · 2023
    10. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    11. Alopecia Areata: An Updated Review for 2023 Journal of Cutaneous Medicine and Surgery · 2023
    12. Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response Journal of the American Academy of Dermatology · 2023